A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU Int. 2005 May; 95(7):963-8.